AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00625326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00625326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-121
Description: 150 µg/g COL-121 Ointment
Study NCT00625326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-121
Description: 300 µg/g COL-121 Ointment
Study NCT01196117 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 14 days of placebo therapy
Description: 14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
Study NCT01196117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of CPAP therapy
Description: 14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
Study NCT01911104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 weeks of aerobic exercise
Study NCT04474093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)
Study NCT00579878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate-Sulfasalazine-Hydroxychloroquine
Description: Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
Study NCT00579878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide-Sulfasalazine-Hydroxychloroquine
Description: Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
Study NCT02128932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
Study NCT04115033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-stim
Description: The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
Study NCT02128932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
Study NCT03414229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg bid days 1-21
Study NCT03414229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/dose Day 1, Q 3 weeks
Study NCT01663025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Reflexology
Description: The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
Study NCT02837146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
Study NCT02837146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colocare Instruction Sheet: SAM + CAM SMOG
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT01276990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 224436
Description: Oral drinking solution
Study NCT01276990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drinking solution
Study NCT02955069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
Study NCT03701230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low temperature rota-flush solution
Description: Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
Study NCT01424579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
Study NCT01424579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diactuaneous Fibrolysis
Description: Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
Study NCT01048853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymphatic mapping with sentinel lymph node biopsy
Study NCT01424579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized physiotherapeutic Treatment
Description: Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
Study NCT01424579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protocolized physiotherapeutic Treatment
Description: Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
Study NCT01424579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protocolized physiotherapeutic Treatment
Description: Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
Study NCT01971892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Invasive ventilation (facial mask and NIV ventilator)
Description: Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
Study NCT01971892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy with facial mask
Description: facial Venturi mask
Study NCT00401154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stationary Cycling
Description: Use of a stationary bicycle for exercise
Study NCT02856087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose Remifentanil
Description: remifentanil infusion at 4ng/ml of Ce
Study NCT02856087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Remifentanil
Description: remifentanil infusion at 4ng/ml of Ce
Study NCT02856087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: naloxone infusion
Study NCT02856087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose remifentanil
Description: remifentanil infusion at 1ng/ml of Ce
Study NCT02856087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: normal saline infusion
Study NCT02856087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline infusion
Study NCT01048853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01048853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingo-Oophorectomy
Description: Undergo hysterectomy with or without salpingo-oophorectomy
Study NCT02023008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: yoga therapy
Description: Undergo integral yoga intervention with videoconferencing
Study NCT02023008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Undergo integral yoga intervention with videoconferencing
Study NCT02023008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01048853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo lymphatic mapping with sentinel lymph node biopsy
Study NCT01048853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo hysterectomy with or without salpingo-oophorectomy
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT00628940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET images with 18F-fluoromethylcholine
Description: sequential PET images with 18F-fluoromethylcholine
Study NCT02735486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger drink
Description: 300 ml ginger drink
Study NCT02735486 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Super pure water
Description: Placebo: Super pure water
Study NCT02117401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating SMOG - 5th Grade Level
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colocare Instruction Video: Modified SAM + CAM -Superior rating
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colocare Instruction Sheet: SAM + CAM Cloze Procedure
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC Colorectal cancer screening for life brochure: SAM + CAM Cloze Procedure
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colocare Instruction Sheet: SAM + CAM - Superior rating Cloze Procedure
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT04500171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating Cloze Procedure
Description: Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
Study NCT02233114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogic exercises
Description: Yogic exercises (YE) - 2 hours per week, 1h in each session
Study NCT02233114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
Study NCT01952197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Leg Raise
Description: The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
Study NCT04160468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exebacase
Description: Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
Study NCT04160468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
Study NCT04167735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without Reverberation Canceller (RevC).
Description: Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
Study NCT04167735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid Reverberation Canceller enabled (RevC_1)
Description: Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
Study NCT02142192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study NCT03255291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment App
Description: The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
Study NCT04313426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
Study NCT02117401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study NCT02913820 — intervention group
Intervention type: OTHER
Intervention: snowfall > 5cm/day
Description: the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
Study NCT03762837 — intervention group
Intervention type: OTHER
Intervention: Benigh gallbladder diseases
Description: We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
Study NCT00735930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV
Study NCT00735930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00735930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00735930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04529876 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: Tofacitinib claim is used as the reference group.
Study NCT04529876 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Description: Abatacept claim is used as the exposure group.
Study NCT04674982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a vibrating device
Description: vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
Study NCT03002792 — intervention group
Intervention type: PROCEDURE
Intervention: general anesthesia
Description: nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
Study NCT02537509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT02537509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of cholecalciferol
Study NCT01040793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744)
Description: Comparison of low and high dose on exercise endurance time in COPD patients
Study NCT02287779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Study NCT02287779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01836757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MethylSulfonylMethane (MSM)
Description: Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
Study NCT01836757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo